Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
Camille LucidarmeAntoine PetitcollinCharlène BrochardLaurent SiproudhisMarie DewitteAmandine LandemaineEric BellissantGuillaume BouguenPublished in: Alimentary pharmacology & therapeutics (2019)
The use of trough levels to assess the feasibility of dose de-escalation seems to be a prerequisite for decreasing the risk of relapse.